Cargando…

SIRT3 inhibits cardiac hypertrophy by regulating PARP-1 activity

Sirtuin 3 (SIRT3) is a type III histone deacetylase that inhibits cardiac hypertrophy. It is mainly localized in the mitochondria and is thus implicated in mitochondrial metabolism. Recent studies have shown that SIRT3 can also accumulate in the nuclear under stressed conditions, and participated in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Xiaojun, Wang, Yanan, Chen, Wenxu, Xu, Suowen, Li, Lingli, Geng, Yadi, Shen, Aizong, Gao, Hui, Zhang, Lei, Liu, Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093179/ https://www.ncbi.nlm.nih.gov/pubmed/32139662 http://dx.doi.org/10.18632/aging.102862

Ejemplares similares

Quercetin Attenuates Cardiac Hypertrophy by Inhibiting Mitochondrial Dysfunction Through SIRT3/PARP-1 Pathway
por: Chen, Wen-Jing, et al.
Publicado: (2021)

MicroRNA-497 Inhibits Cardiac Hypertrophy by Targeting Sirt4
por: Xiao, Yimin, et al.
Publicado: (2016)

Circ-SIRT1 inhibits cardiac hypertrophy via activating SIRT1 to promote autophagy
por: Wang, Weichen, et al.
Publicado: (2021)

The lncRNA-GAS5/miR-221-3p/DKK2 Axis Modulates ABCB1-Mediated Adriamycin Resistance of Breast Cancer via the Wnt/β-Catenin Signaling Pathway
por: Chen, Zhaolin, et al.
Publicado: (2020)

SIRT2 inhibition protects against cardiac hypertrophy and ischemic injury
por: Yang, Xiaoyan, et al.
Publicado: (2023)

Hydrogen Sulfide (H(2)S)-Releasing Compounds: Therapeutic Potential in Cardiovascular Diseases
por: Zhang, Lei, et al.
Publicado: (2018)

Metformin and Vascular Diseases: A Focused Review on Smooth Muscle Cell Function
por: Deng, Mingying, et al.
Publicado: (2020)

BAF155 promotes cardiac hypertrophy and fibrosis through inhibition of WWP2-mediated PARP1 ubiquitination
por: Zhang, Naijin, et al.
Publicado: (2023)

Deubiquitinase Ubiquitin‐Specific Protease 10 Deficiency Regulates Sirt6 signaling and Exacerbates Cardiac Hypertrophy
por: Zhang, Dian‐Hong, et al.
Publicado: (2020)

Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial SIRT3
por: Pillai, Vinodkumar B., et al.
Publicado: (2015)

PHD Finger Protein 19 Promotes Cardiac Hypertrophy via Epigenetically Regulating SIRT2
por: Gu, Wei, et al.
Publicado: (2021)

Increased SIRT3 combined with PARP inhibition rescues motor function of SBMA mice
por: Garcia Castro, David R., et al.
Publicado: (2023)

Myotubularin-related protein 14 suppresses cardiac hypertrophy by inhibiting Akt
por: Zhang, Jie-Lei, et al.
Publicado: (2020)

The poly(ADP-ribosyl)ation of BRD4 mediated by PARP1 promoted pathological cardiac hypertrophy
por: Li, Zhenzhen, et al.
Publicado: (2021)

Sinapic Acid Inhibits Cardiac Hypertrophy via Activation of Mitochondrial Sirt3/SOD2 Signaling in Neonatal Rat Cardiomyocytes
por: Yun, Ui Jeong, et al.
Publicado: (2020)

Inhibition of AKT induces p53/SIRT6/PARP1-dependent parthanatos to suppress tumor growth
por: Zhang, Yizheng, et al.
Publicado: (2022)

Deacetylation-dependent regulation of PARP1 by SIRT2 dictates ubiquitination of PARP1 in oxidative stress-induced vascular injury
por: Zhang, Naijin, et al.
Publicado: (2021)

Metformin, Macrophage Dysfunction and Atherosclerosis
por: Feng, Xiaojun, et al.
Publicado: (2021)

Toll-like receptors in cardiac hypertrophy
por: Zhang, Yanan, et al.
Publicado: (2023)

SIRT1/PARP1 crosstalk: connecting DNA damage and metabolism
por: Luna, Augustin, et al.
Publicado: (2013)

Upregulation of M(3) muscarinic receptor inhibits cardiac hypertrophy induced by angiotensin II
por: Liu, Yan, et al.
Publicado: (2013)

Fibroblast growth factor 20 attenuates pathological cardiac hypertrophy by activating the SIRT1 signaling pathway
por: Chen, Yunjie, et al.
Publicado: (2022)

Inhibition of PIKfyve prevents myocardial apoptosis and hypertrophy through activation of SIRT3 in obese mice
por: Tronchere, Helene, et al.
Publicado: (2017)

Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy
por: Hafner, Angela V., et al.
Publicado: (2010)

Interference between PARPs and SIRT1: a novel approach to healthy ageing?
por: CantÓ, Carles, et al.
Publicado: (2011)

Dihydromyricetin Attenuates Myocardial Hypertrophy Induced by Transverse Aortic Constriction via Oxidative Stress Inhibition and SIRT3 Pathway Enhancement
por: Chen, Yun, et al.
Publicado: (2018)

The nuclear sirtuin SIRT6 protects the heart from developing aging-associated myocyte senescence and cardiac hypertrophy
por: Pillai, Vinodkumar B., et al.
Publicado: (2021)

SIRT3 improved peroxisomes-mitochondria interplay and prevented cardiac hypertrophy via preserving PEX5 expression
por: Wang, Minghui, et al.
Publicado: (2023)

ICS II protects against cardiac hypertrophy by regulating metabolic remodelling, not by inhibiting autophagy
por: Han, Dongjian, et al.
Publicado: (2020)

Cardiac Hypertrophy
por: DaCosta,
Publicado: (1891)

Cardiac Hypertrophy is Positively Regulated by MicroRNA-24 in Rats
por: Gao, Juan, et al.
Publicado: (2018)

Uncoupling of PARP1 Trapping and Inhibition Using Selective PARP1 Degradation
por: Wang, Shuai, et al.
Publicado: (2019)

A NFAT decoy approach to inhibit cardiac hypertrophy
por: Heineke, Joerg
Publicado: (2021)

SIRT6 Suppresses NFATc4 Expression and Activation in Cardiomyocyte Hypertrophy
por: Li, Zhenzhen, et al.
Publicado: (2019)

PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1
por: Pinton, Giulia, et al.
Publicado: (2013)

Role of PTEN-less in cardiac injury, hypertrophy and regeneration
por: Liang, Tian, et al.
Publicado: (2021)

Exogenous NADPH exerts a positive inotropic effect and enhances energy metabolism via SIRT3 in pathological cardiac hypertrophy and heart failure
por: Qian, Ke, et al.
Publicado: (2023)

Circular RNAs in the regulation of cardiac hypertrophy
por: Wu, Siyi, et al.
Publicado: (2021)

The cross-talk between PARylation and SUMOylation in C/EBPβ at K134 site participates in pathological cardiac hypertrophy
por: Wang, Luping, et al.
Publicado: (2022)

miR-139-5p inhibits isoproterenol-induced cardiac hypertrophy by targetting c-Jun
por: Ming, Su, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9kmlrvpc9sghskb8ngm7pe8auo